120 related articles for article (PubMed ID: 2169786)
1. The role of specific 5-HT3 receptor antagonism in the control of cytostatic drug-induced emesis.
Blower PR
Eur J Cancer; 1990; 26 Suppl 1():S8-11. PubMed ID: 2169786
[TBL] [Abstract][Full Text] [Related]
2. RG 12915: a potent 5-hydroxytryptamine-3 antagonist that is an orally effective inhibitor of cytotoxic drug-induced emesis in the ferret and dog.
Fitzpatrick LR; Lambert RM; Pendley CE; Martin GE; Bostwick JS; Gessner GW; Airey JE; Youssefyeh RD; Pendleton RG; Decktor DL
J Pharmacol Exp Ther; 1990 Aug; 254(2):450-5. PubMed ID: 2166791
[TBL] [Abstract][Full Text] [Related]
3. Effects of granisetron, a selective 5-HT3 receptor antagonist, on ouabain-induced emesis in ferrets.
Endo T; Sugawara J; Nemoto M; Minami M; Blower PR
Res Commun Mol Pathol Pharmacol; 1998 Dec; 102(3):227-39. PubMed ID: 10342910
[TBL] [Abstract][Full Text] [Related]
4. The symptomatic control of cytostatic drug-induced emesis. A recent history and review.
Joss RA; Brand BC; Buser KS; Cerny T
Eur J Cancer; 1990; 26 Suppl 1():S2-8. PubMed ID: 2169781
[TBL] [Abstract][Full Text] [Related]
5. DAT-582, a novel serotonin3 receptor antagonist, is a potent and long-lasting antiemetic agent in the ferret and dog.
Yoshida N; Omoya H; Ito T
J Pharmacol Exp Ther; 1992 Mar; 260(3):1159-65. PubMed ID: 1532032
[TBL] [Abstract][Full Text] [Related]
6. An overview on the use of granisetron in the treatment of emesis associated with cytostatic chemotherapy.
Tabona MV
Eur J Cancer; 1990; 26 Suppl 1():S37-44. PubMed ID: 2169785
[TBL] [Abstract][Full Text] [Related]
7. Effects of granisetron, a 5-HT3 receptor antagonist, on 5-hydroxytryptamine (5-HT) release from the isolated ileum in a delayed-emesis rat model.
Endo T; Hamaue N; Ihira E; Teramoto Y; Liu Y; Hirafuji M; Minami M
Res Commun Mol Pathol Pharmacol; 2002; 111(1-4):55-68. PubMed ID: 14632314
[TBL] [Abstract][Full Text] [Related]
8. Effects of various 5-HT3 receptor antagonists, granisetron, ondansetron, ramosetron and azasetron on serotonin (5-HT) release from the ferret isolated ileum.
Endo T; Minami M; Kitamura N; Teramoto Y; Ogawa T; Nemoto M; Hamaue N; Hirafuji M; Yasuda E; Blower PR
Res Commun Mol Pathol Pharmacol; 1999; 104(2):145-55. PubMed ID: 10634307
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological characterization of RS 25259-197, a novel and selective 5-HT3 receptor antagonist, in vivo.
Eglen RM; Lee CH; Smith WL; Johnson LG; Clark R; Whiting RL; Hegde SS
Br J Pharmacol; 1995 Feb; 114(4):860-6. PubMed ID: 7773547
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and structure-affinity relationships of novel N-(1-ethyl-4-methylhexahydro-1,4-diazepin-6-yl)pyridine-3-carboxamides with potent serotonin 5-HT3 and dopamine D2 receptor antagonistic activity.
Hirokawa Y; Fujiwara I; Suzuki K; Harada H; Yoshikawa T; Yoshida N; Kato S
J Med Chem; 2003 Feb; 46(5):702-15. PubMed ID: 12593651
[TBL] [Abstract][Full Text] [Related]
11. BMY-25801, an antiemetic agent free of D2-dopamine receptor antagonist properties.
Gylys JA; Wright RN; Nicolosi WD; Buyniski JP; Crenshaw RR
J Pharmacol Exp Ther; 1988 Mar; 244(3):830-7. PubMed ID: 2978041
[TBL] [Abstract][Full Text] [Related]
12. Granisetron, a 5-HT3 receptor antagonist, inhibited cisplatin-induced 5-hydroxytryptamine release in the isolated ileum of ferrets.
Endo T; Ogawa T; Hamaue N; Akita K; Hirafuji M; Minami M; Blower PR
Res Commun Mol Pathol Pharmacol; 1998 Jun; 100(3):243-53. PubMed ID: 9730004
[TBL] [Abstract][Full Text] [Related]
13. The broad-spectrum anti-emetic activity of AS-8112, a novel dopamine D2, D3 and 5-HT3 receptors antagonist.
Yoshikawa T; Yoshida N; Oka M
Br J Pharmacol; 2001 May; 133(2):253-60. PubMed ID: 11350861
[TBL] [Abstract][Full Text] [Related]
14. Phenylimidazolidin-2-one derivatives as selective 5-HT3 receptor antagonists and refinement of the pharmacophore model for 5-HT3 receptor binding.
Heidempergher F; Pillan A; Pinciroli V; Vaghi F; Arrigoni C; Bolis G; Caccia C; Dho L; McArthur R; Varasi M
J Med Chem; 1997 Oct; 40(21):3369-80. PubMed ID: 9341912
[TBL] [Abstract][Full Text] [Related]
15. Repeated administration of the 5-HT3 receptor antagonist granisetron reduces the incidence of delayed cisplatin-induced emesis in the piglet.
Grélot L; Le Stunff H; Milano S; Blower PR; Romain D
J Pharmacol Exp Ther; 1996 Oct; 279(1):255-61. PubMed ID: 8859001
[TBL] [Abstract][Full Text] [Related]
16. [Effect of the 5-HT3 receptor antagonist granisetron on estramustine phosphate sodium (Estracyt)-induced emesis in ferrets].
Higashioka M; Yamaguchi E; Takatori S; Tanaka M; Kyoi T
Hinyokika Kiyo; 2010 Jul; 56(7):361-5. PubMed ID: 20724808
[TBL] [Abstract][Full Text] [Related]
17. New 2-piperazinylbenzimidazole derivatives as 5-HT3 antagonists. Synthesis and pharmacological evaluation.
Orjales A; Mosquera R; Labeaga L; Rodes R
J Med Chem; 1997 Feb; 40(4):586-93. PubMed ID: 9046349
[TBL] [Abstract][Full Text] [Related]
18. [BRL 43694A--a 5-hydroxytryptamine receptor blocker as an antiemetic in cytostatic therapy].
Joss R; Rohrbach D; Buser K; Pirovino M; Karde C; Brunner K
Schweiz Med Wochenschr; 1989 Jun; 119(23):831-4. PubMed ID: 2549616
[TBL] [Abstract][Full Text] [Related]
19. Granisetron: is there a dose-response effect on nausea and vomiting?
Minami M
Cancer Chemother Pharmacol; 2003 Aug; 52(2):89-98. PubMed ID: 12783208
[TBL] [Abstract][Full Text] [Related]
20. Preclinical pharmacology of a new serotonergic receptor antagonist, LY281067.
Cohen ML; Fuller RW; Kurz KD; Parli CJ; Mason NR; Meyers DB; Smallwood JK; Toomey RE
J Pharmacol Exp Ther; 1988 Jan; 244(1):106-12. PubMed ID: 3335993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
